Page 41 - GTM-1-2

Global Translational Medicine

ORIGINAL RESEARCH ARTICLE
The status of compensated cirrhosis might

be negatively associated with the tumor
size in patients with hepatitis B virus-related

hepatocellular carcinoma

Yanna Liu , Xiangjun Qian , Congying Wu , Weidong Pan , Jingmin Zhao ,
3
2†
1†
2
4
Xiangmei Chen *, and Fengmin Lu *
1
1,5
1 Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking
University Health Science Center, Peking University, Beijing 100191, China
2 Department of Pancreatic-Hepatobiliary Surgery, The Sixth Affiliated Hospital of Sun Yat-sen
University, Guangzhou 510655, China
3 Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of
Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing
100191, China
4 Department of Pathology and Hepatology, Fifth Medical Center of Chinese PLA General Hospital,
Beijing 100039, China
5 Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University,
Zhengzhou 450001, China
† These authors contributed equally
to this work.
Corresponding authors: Abstract
Fengmin Lu
(lu.fengmin@hsc.pku.edu.cn) Liver cirrhosis has been a well-known risk factor for the development of hepatocellular
carcinoma (HCC). However, this view has recently been challenged. This study aimed
Xiangmei Chen to investigate the potential association of cirrhosis with hepatitis B virus (HBV)-related
(xm_chen6176@bjmu.edu.cn)
HCC. In this study, two independent multicenter clinical cohorts that included 1,431
Citation: Liu Y, Qian X, Wu C, HCC patients with chronic HBV infection were retrospectively studied. The first cohort
et al., 2022, The status of
compensated cirrhosis might be consisted of 334 HCC patients undergoing curative resection and cirrhosis, who have
negatively associated with the been pathologically diagnosed. The second cohort consisted of 1,087 HCC patients, who
tumor size in patients with hepatitis have been diagnosed for the presence of cirrhosis based on clinical evidence. Patients
B virus-related hepatocellular
carcinoma. Global Transl Med, of each cohort were further divided into different subgroups according to the presence
1(2):1. of cirrhosis and the severity of the cirrhosis. In both cohorts, patients with cirrhosis
https://doi.org/10.36922/gtm.v1i2.94 had smaller tumor size compared to those without cirrhosis (P < 0.05) and a relatively
Received: May 12, 2022 lower proportion of large tumor, defined as tumor size > 5 cm in diameter (P < 0.05).
Accepted: July 22, 2022 Patients with decompensated cirrhosis had the highest rate of vascular invasion and/
Published Online: August 12, 2022 or extrahepatic metastases compared with compensated cirrhosis and non-cirrhosis
Copyright: © 2022 Author(s). (53.0% vs. 24.8% vs. 26.9%, P < 0.001). In the first cohort, globulin (odds ratio [OR] =
This is an Open Access article 1.096, P = 0.001) and vascular invasion (OR = 4.013, P = 0.013) were independent risk
distributed under the terms of the
Creative Commons Attribution predictors of HCC tumor size >5 cm, while cirrhosis stage Laennec 4B/C was a protective
License, permitting distribution, factor (OR = 0.372, P = 0.002). Similar results were observed in the second cohort. In
and reproduction in any medium, conclusion, this study implied that HCC patients with compensated cirrhosis tend to
provided the original work is
properly cited. harbor smaller tumor, but severe cirrhosis favors tumor vascular invasion and metastasis.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Liver cirrhosis; Hepatocellular carcinoma; Hepatitis B virus; Neoplasm
regard to jurisdictional claims in
published maps and institutional metastasis; Vascular invasion
affiliations.

Volume 1 Issue 2 (2022) 1 https://doi.org/10.36922/gtm.v1i2.94